The risk of thromboembolism in heart failure: Does it merit anticoagulation therapy?

American Journal of Cardiology

Volumn 107, Issue 4, 2011, Pages 558-560

  Shantsila, Eduard ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN;

ANTICOAGULATION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); HEART FAILURE; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; RISK FACTOR; STROKE; THROMBOEMBOLISM;

EID: 79551664831     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.10.029     Document Type: Editorial

References (22)

1. S. Rietbrock, J.M. Plumb, A.M. Gallagher, and T.P. van Staa How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database Thromb Haemost 101 2009 527 534
2. M. Hughes, G.Y. Lip Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data Thromb Haemost 99 2008 295 304
3. E. Shantsila, and G.Y. Lip The endothelium and thrombotic risk in heart failure Thromb Haemost 102 2009 185 187
4. A.Y. Chong, G.Y. Lip, B. Freestone, and A.D. Blann Increased circulating endothelial cells in acute heart failure: comparison with von Willebrand factor and soluble E-selectin Eur J Heart Fail 8 2006 167 172
5. G.Y. Lip, and C.R. Gibbs Does heart failure confer a hypercoagulable state? Virchows triad revisited J Am Coll Cardiol 33 1999 1424 1426
6. B. Jug, N. Vene, B.G. Salobir, M. Sebestjen, M. Sabovic, and I. Keber Prognostic impact of haemostatic derangements in chronic heart failure Thromb Haemost 102 2009 314 320
7. T. Gombos, V. Mak, L. Cervenak, J. Papassotiriou, J. Kunde, J. Hrsfalvi, Z. Frhcz, Z. Pozsonyi, G. Borgulya, L. Jnoskuti, and Z. Prohszka Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure Thromb Haemost 102 2009 573 580
8. E. Sbarouni, A. Bradshaw, F. Andreotti, E. Tuddenham, C.M. Oakley, and J.G. Cleland Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure Am Heart J 127 1994 607 612
9. R.S. Freudenberger, A.C. Wilson, J.B. Kostis AFFIRM Investigators and Committees Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM study) Am J Cardiol 100 2007 247 252
10. B.F. Uretsky, K. Thygesen, P.W. Armstrong, J.G. Cleland, J.D. Horowitz, B.M. Massie, M. Packer, P.A. Poole-Wilson, and L. Ryden Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial Circulation 102 2000 611 616
11. D.L. Dries, Y.D. Rosenberg, M.A. Waclawiw, and M.J. Domanski Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials J Am Coll Cardiol 29 1997 1074 1080
12. E. Loh, M.S. Sutton, C.C. Wun, J.L. Rouleau, G.C. Flaker, S.S. Gottlieb, G.A. Lamas, L.A. Moy, S.Z. Goldhaber, and M.A. Pfeffer Ventricular dysfunction and the risk of stroke after myocardial infarction N Engl J Med 336 1997 251 257
13. R.S. Freudenberger, A.S. Hellkamp, J.L. Halperin, J. Poole, J. Anderson, G. Johnson, D.B. Mark, K.L. Lee, G.H. Bardy SCD-HeFT Investigators Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Circulation 115 2007 2637 2641 (Pubitemid 46791362)
14. W.B. Dunkman, G.R. Johnson, P.E. Carson, G. Bhat, L. Farrell, J.N. Cohn The V-HeFT VA Cooperative Studies Group Incidence of thromboembolic events in congestive heart failure Circulation 87 1993 VI94 VI101
15. J.G. Cleland, I. Findlay, S. Jafri, G. Sutton, R. Falk, C. Bulpitt, C. Prentice, I. Ford, A. Trainer, and P.A. Poole-Wilson The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure Am Heart J 148 2004 157 164
16. B.M. Massie, J.F. Collins, S.E. Ammon, P.W. Armstrong, J.G. Cleland, M. Ezekowitz, S.M. Jafri, W.F. Krol, C.M. OConnor, K.A. Schulman, K. Teo, S.R. Warren WATCH Trial Investigators Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial Circulation 119 2009 1616 1624
17. D.V. Cokkinos, G.C. Haralabopoulos, J.B. Kostis, P.K. Toutouzas HELAS investigators Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study Eur J Heart Fail 8 2006 428 432
18. M. Mujib, A.A.Z. Rahman, R.V. Desai, M.I. Ahmed, M.A. Feller, I. Aban, T.E. Love, M. White, P. Deedwania, W.S. Aronow, G. Fonarow, and A. Ahmed Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves Am J Cardiol 107 2010 552 557
19. J. Hirsh, V. Fuster, J. Ansell, and J.L.American Heart Association/American College of Cardiology Foundation. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J Am Coll Cardiol 41 2003 1633 1652 (Pubitemid 36543387)
20. G.W. Albers, P. Amarenco, J.D. Easton, R.L. Sacco, and P. Teal Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 483S 512S
21. K. Swedberg, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O.A. Smiseth, A. Gavazzi, A. Haverich, A. Hoes, T. Jaarsma, J. Korewicki, S. Lvy, C. Linde, J.L. Lopez-Sendon, M.S. Nieminen, L. Pirard, W.J. Remme Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 1115 1140
22. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey Chest 138 2010 1093 1100